Biologics Manufacturers Need More Adaptable, Modular Strategies: Tufts Study

Clinical Trials Advisor
A A
Makers of biopharmaceuticals will need to become more modular and agile to adjust for trends in personalized medicine and oncology, according to the Tufts Center for the Study of Drug Development.

To View This Article:

Login

Subscribe To Clinical Trials Advisor